Please use this identifier to cite or link to this item: /library/oar/handle/123456789/139554
Title: Monotherapy versus dual lipid lowering therapy in high risk coronary artery disease patients
Authors: Spiteri, Shanice
Wirth, Francesca
Gauci, Marilyn
Desira, Josette
Abela, Mark
Xuereb, Robert G.
Cassar Maempel, Andrew
Camilleri, Liberato
Azzopardi, Lilian M.
Keywords: Coronary heart disease -- Treatment
Coronary heart disease -- Patients
Coronary artery disease -- Treatment
Antilipemic agents -- Therapeutic use
Statins (Cardiovascular agents)
Issue Date: 2025
Publisher: University of Malta. Department of Pharmacy
Citation: ³§±è¾±³Ù±ð°ù¾±,&#³æ20;³§.,&#³æ20;°Â¾±°ù³Ù³ó,&#³æ20;¹ó.,&#³æ20;³Ò²¹³Ü³¦¾±,&#³æ20;²Ñ.,&#³æ20;¶Ù±ð²õ¾±°ù²¹,&#³æ20;´³.,&#³æ20;´¡²ú±ð±ô²¹,&#³æ20;²Ñ.,&#³æ20;³Ý³Ü±ð°ù±ð²ú,&#³æ20;¸é.&#³æ20;³Ò.,…A³ú³ú´Ç±è²¹°ù»å¾±,&#³æ20;³¢.&#³æ20;²Ñ.&#³æ20;(2025).&#³æ20;²Ñ´Ç²Ô´Ç³Ù³ó±ð°ù²¹±è²â&#³æ20;±¹±ð°ù²õ³Ü²õ&#³æ20;»å³Ü²¹±ô&#³æ20;±ô¾±±è¾±»å&#³æ20;±ô´Ç·É±ð°ù¾±²Ô²µ&#³æ20;³Ù³ó±ð°ù²¹±è²â&#³æ20;¾±²Ô&#³æ20;³ó¾±²µ³ó&#³æ20;°ù¾±²õ°ì&#³æ20;³¦´Ç°ù´Ç²Ô²¹°ù²â&#³æ20;²¹°ù³Ù±ð°ù²â&#³æ20;»å¾±²õ±ð²¹²õ±ð&#³æ20;±è²¹³Ù¾±±ð²Ô³Ù²õ.&#³æ20;±Ê´Ç²õ³Ù±ð°ù&#³æ20;²õ±ð²õ²õ¾±´Ç²Ô&#³æ20;±è°ù±ð²õ±ð²Ô³Ù±ð»å&#³æ20;²¹³Ù&#³æ20;³Ù³ó±ð&#³æ20;83°ù»å&#³æ20;¹ó±õ±Ê&#³æ20;°Â´Ç°ù±ô»å&#³æ20;°ä´Ç²Ô²µ°ù±ð²õ²õ&#³æ20;´Ç´Ú&#³æ20;±Ê³ó²¹°ù³¾²¹³¦²â&#³æ20;²¹²Ô»å&#³æ20;±Ê³ó²¹°ù³¾²¹³¦±ð³Ü³Ù¾±³¦²¹±ô&#³æ20;³§³¦¾±±ð²Ô³¦±ð²õ,&#³æ20;°ä´Ç±è±ð²Ô³ó²¹²µ±ð²Ô.
Abstract: Introduction: European Society of Cardiology guidelines for the management of dyslipidaemias recommend dual therapy with a high intensity statin and ezetimibe if target low density lipoprotein cholesterol, LDL-C 1 4 mmol/L) is not achieved with statin monotherapy.
Aim: To assess lipid lowering therapy and LDL-C levels in coronary artery disease (CAD) patients who underwent a cardiac intervention.
URI: https://www.um.edu.mt/library/oar/handle/123456789/139554
Appears in Collections:Scholarly Works - FacM&SPha



Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.